Showing results (101-110 of 181) with videos related to
Sort By:
Pageof 19
The Journal of Clinical Investigation|February 1, 1994
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomasJ A Kern, R J Slebos, B Top, et al.Cancer Investigation|January 1, 1995
Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancerS Rodenhuis, E van der Wall, W W ten Bokkel Huinink, et al.Genes, Chromosomes & Cancer|February 1, 1995
N- and KRAS mutations in primary testicular germ cell tumors: incidence and possible biological implicationsR A Olie, L H Looijenga, L Boerrigter, et al.Therapeutic Drug Monitoring|October 1, 1995
Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?L J van Warmerdam, O van Tellingen, W W ten Bokkel Huinink, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1997
Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancerW W ten Bokkel Huinink, L J van Warmerdam, T J Helmerhorst, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1993
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative GroupJ B Vermorken, J Verweij, P H de Mulder, et al.Seminars in Oncology|February 1, 1997
Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding studyW ten Bokkel Huinink, C Veenhof, M Huizing, et al.The British Journal of Surgery|May 20, 2017
Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapyB B Koolen, M Donker, M E Straver, et al.Journal of the National Cancer Institute|February 14, 1998
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapyF S van Dam, S B Schagen, M J Muller, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of ageS Mook, M K Schmidt, B Weigelt, et al.Pageof 19